SummaryEligible participants will be randomly allocated to one of two experimental arms. In Experimental Arm A, participants will receive immunotherapy (pembrolizumab) and targeted therapy (sacituzumab govitecan). They will receive sacituzumab govitecan (10mg/kg via intravenous [IV] infusion) once weekly on Day 1 and Day 8 of a continuous 21-day cycle, plus pembrolizumab (200mg via IV infusion) on Day 1 every 3 weeks. In Experimental Arm B, participants will receive immunotherapy (pembrolizumab) alone. Pembrolizumab (200mg via IV infusion) will be given on Day 1 every 3 weeks.
Treatment TypeRadiotherapy,Systemic therapy (chemotherapy, hormone therapy or immunotherapy)
Use the hyperlinks, where available to access additional clinical trial information.
Merck Sharp & Dohme LLC
An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)